Literature DB >> 12933407

Intravenous remifentanil produces withdrawal hyperalgesia in volunteers with capsaicin-induced hyperalgesia.

David D Hood1, Regina Curry, James C Eisenach.   

Abstract

Opioids administered during surgery may be beneficial by preempting postoperative pain or detrimental by causing acute tolerance. We used a stable model of hyperalgesia in volunteers to test whether acute opioid exposure also results in such pain sensitization over a period of hours in humans. Ten healthy volunteers were studied. Areas of mechanical hyperalgesia and allodynia were induced by topical capsaicin application plus intermittent heating. Computer-controlled IV remifentanil infusion was titrated to a targeted plasma concentration that reduced pain report to noxious heat by 70% and was maintained at this level for 60-100 min. Areas of hyperalgesia and allodynia were measured during and after remifentanil infusion. Remifentanil (targeted concentration of 3.1 +/- 1.2 ng/mL) reduced areas of hyperalgesia and allodynia by 33% +/- 31% and 65% +/- 28%, respectively, during infusion (P < 0.05). Areas of hyperalgesia and allodynia continuously enlarged 4 h after remifentanil was stopped, to 180% +/- 47% and 180% +/- 86%, respectively. This study demonstrates that acute opioid exposure enhances hypersensitivity for hours after exposure. If applicable to the surgical setting, this could increase the dose of opioid required for postoperative analgesia and enhance, rather than inhibit, postoperative pain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12933407     DOI: 10.1213/01.ane.0000078811.80093.88

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  38 in total

Review 1.  [Do opioids induce hyperalgesia?].

Authors:  C Zöllner
Journal:  Anaesthesist       Date:  2010-11       Impact factor: 1.041

2.  Opioid-induced latent sensitization in a model of non-inflammatory viscerosomatic hypersensitivity.

Authors:  Bo Lian; Louis Vera-Portocarrero; Tamara King; Michael H Ossipov; Frank Porreca
Journal:  Brain Res       Date:  2010-08-19       Impact factor: 3.252

Review 3.  Perioperative Hyperalgesia and Associated Clinical Factors.

Authors:  Obaid S Malik; Alan D Kaye; Richard D Urman
Journal:  Curr Pain Headache Rep       Date:  2017-01

4.  A genetic analysis of opioid-induced hyperalgesia in mice.

Authors:  De-Yong Liang; Guochun Liao; Jianmei Wang; Jonathan Usuka; YingYing Guo; Gary Peltz; J David Clark
Journal:  Anesthesiology       Date:  2006-05       Impact factor: 7.892

5.  [Opioid-induced analgesia and hyperalgesia].

Authors:  W Koppert
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

Review 6.  Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon?

Authors:  D Andrew Tompkins; Claudia M Campbell
Journal:  Curr Pain Headache Rep       Date:  2011-04

7.  Altered quantitative sensory testing outcome in subjects with opioid therapy.

Authors:  Lucy Chen; Charlene Malarick; Lindsey Seefeld; Shuxing Wang; Mary Houghton; Jianren Mao
Journal:  Pain       Date:  2009-02-23       Impact factor: 6.961

8.  The effect of anesthetic technique on early postoperative gastric emptying: comparison of propofol-remifentanil and opioid-free sevoflurane anesthesia.

Authors:  Jakob Walldén; Sven-Egron Thörn; Asa Lövqvist; Lisbeth Wattwil; Magnus Wattwil
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

9.  The effect of repeated intramuscular alfentanil injections on experimental pain and abuse liability indices in healthy males.

Authors:  David Andrew Tompkins; Michael T Smith; George E Bigelow; Ruin Moaddel; Swarajya Lakshmi Vatem Venkata; Eric C Strain
Journal:  Clin J Pain       Date:  2014-01       Impact factor: 3.442

Review 10.  Assessing analgesic actions of opioids by experimental pain models in healthy volunteers - an updated review.

Authors:  Camilla Staahl; Anne Estrup Olesen; Trine Andresen; Lars Arendt-Nielsen; Asbjørn Mohr Drewes
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.